GPCM
STRO icon

Granite Point Capital Management’s Sutro Biopharma STRO Stock Holding History

Granite Point Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,722
Closed -$1.48M – 202
2020
Q3 		$1.48M Sell
14,722
-278
-2% -$26.3K 0.08% 101
2020
Q2 		$1.16M Buy
15,000
+7,936
+112% +$762K 0.06% 105
2020
Q1 		$721K Sell
7,064
-2,936
-29% -$309K 0.41% 54
2019
Q4 		$1.1M Buy
+10,000
New +$1.03M 0.17% 53

Other funds holding STRO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Granite Point Capital Management's STRO Position: Q4 2020 in Review

Granite Point Capital Management sold out of Sutro Biopharma (STRO) in Q4 2020, closing a stake of 14,722 shares — an estimated $1.48M sold.

Granite Point Capital Management first reported a position in STRO in Q4 2019 and held it in 4 quarters. The position peaked at $1.48M in Q3 2020. 134 funds tracked by Wall St. Rank hold STRO as of Q4 2020.

  • Granite Point Capital Management reported no remaining Sutro Biopharma position as of Q4 2020 after selling out during the quarter.
  • Granite Point Capital Management sold 14,722 Sutro Biopharma shares in Q4 2020, an estimated $1.48M.
  • Granite Point Capital Management first reported a position in Sutro Biopharma in Q4 2019 and held it in 4 quarters.
  • Granite Point Capital Management's Sutro Biopharma position peaked at $1.48M in Q3 2020.
  • 134 funds tracked by Wall St. Rank held Sutro Biopharma as of Q4 2020.

Based on Granite Point Capital Management's 13F filing for Q4 2020, filed 5 Feb 2021.